Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

2018 ◽  
Vol 58 (7) ◽  
pp. 939-951 ◽  
Author(s):  
Yan Xu ◽  
Chuanpu Hu ◽  
Yanli Zhuang ◽  
Benjamin Hsu ◽  
Zhenhua Xu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Monoclonal Antibody ◽  
Interleukin 6 ◽  
Active Rheumatoid Arthritis ◽  
Human Monoclonal Antibody ◽  
Population Pharmacokinetic Analysis ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic ◽  
Antibody Targeting

scholarly journals Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis

2020 ◽  
Author(s):  
Junko Toyoshima ◽  
Mai Shibata ◽  
Atsunori Kaibara ◽  
Yuichiro Kaneko ◽  
Hiroyuki Izutsu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Population Pharmacokinetic Analysis ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic

scholarly journals Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis

2018 ◽  
Vol 84 (4) ◽  
pp. 716-725 ◽  
Author(s):  
Carla Bastida ◽  
Virginia Ruiz-Esquide ◽  
Mariona Pascal ◽  
Aurelia H. M. de Vries Schultink ◽  
Jordi Yagüe ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Population Pharmacokinetic Analysis ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic

scholarly journals A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological Choroidal Neovascularization in Mice

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1308
Author(s):  
Songyi Seo ◽  
Koung Li Kim ◽  
Yeongju Yeo ◽  
Ryul-I Kim ◽  
Hayoung Jeong ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Intravitreal Injection ◽  
Choroidal Neovascularization ◽  
Murine Model ◽  
Human Monoclonal Antibody ◽  
Age Related Macular Degeneration ◽  
Pharmacokinetic Analysis ◽  
Neovascular Amd ◽  
Age Related ◽  
Antibody Targeting

Stem cell factor (SCF) and its receptor, cKIT, are novel regulators of pathological neovascularization in the eye, which suggests that inhibition of SCF/cKIT signaling may be a novel pharmacological strategy for treating neovascular age-related macular degeneration (AMD). This study evaluated the therapeutic potential of a newly developed fully human monoclonal antibody targeting cKIT, NN2101, in a murine model of neovascular AMD. In hypoxic human endothelial cells, NN2101 substantially inhibited the SCF-induced increase in angiogenesis and activation of the cKIT signaling pathway. In a murine model of neovascular AMD, intravitreal injection of NN2101 substantially inhibited the SCF/cKIT-mediated choroidal neovascularization (CNV), with efficacy comparable to aflibercept, a vascular endothelial growth factor inhibitor. A combined intravitreal injection of NN2101 and aflibercept resulted in an additive therapeutic effect on CNV. NN2101 neither caused ocular toxicity nor interfered with the early retinal vascular development in mice. Ocular pharmacokinetic analysis in rabbits indicated that NN2101 demonstrated a pharmacokinetic profile suitable for intravitreal injection. These findings provide the first evidence of the potential use of the anti-cKIT blocking antibody, NN2101, as an alternative or additive therapeutic for the treatment of neovascular AMD.

Sign in / Sign up

Export Citation Format

Share Document